Nelibat (Atorvastatin)

Atorvastatin, the active ingredient in Nelibat, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used in adults with hypercholesterolemia, mixed dyslipidemia, or at risk of cardiovascular events.

GNH USA supplies Nelibat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Nelibat (atorvastatin) is indicated for disorders of lipid metabolism and for reducing cardiovascular risk.

- Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Mixed dyslipidemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Cardiovascular risk reduction: helps prevent myocardial infarction, stroke and other atherosclerotic events in patients with established risk factors.

Atorvastatin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of queasiness. - Constipation: reduced bowel movements. - Elevated liver enzymes: mild increase in transaminases.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Severe liver injury: marked elevation of hepatic enzymes or hepatitis. - Allergic reactions: rash, angioedema, or anaphylaxis. - Pancreatitis: inflammation of the pancreas. - Myopathy with CK elevation: muscle weakness with high creatine kinase. - Hepatitis: inflammation of the liver.

When prescribing Nelibat, clinicians should consider several safety and handling precautions.

- Liver function monitoring: assess baseline transaminases and repeat periodically. - Muscle toxicity vigilance: discontinue if unexplained muscle pain, weakness or CK elevation occurs. - Drug interactions: review concomitant medications that may increase statin levels. - Pregnancy and lactation: contraindicated in pregnancy (Category X) and not recommended while breastfeeding. - Renal or hepatic impairment: dose adjustment may be required in severe disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Atorvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors, nefazodone, grapefruit juice). - Gemfibrozil or other fibrates: increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Amiodarone: may raise atorvastatin levels. - Digoxin: potential for increased serum concentrations. - Warfarin: may enhance anticoagulant effect. - Cyclosporine: can increase statin exposure. - Niacin: higher incidence of muscle toxicity.